1. Australia Stocks

  2. •

    Health technology

  3. •

    Medical specialties
CLEO Diagnostics Ltd

CLEO Diagnostics Ltd

AASX:COV
0.32
AUD
+0.02
(+4.92%)
-0.04EPS
68.56MMarket Cap
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
- -
- -
- -
- -
Basic EPS, GAAP
-0.07
-0.03
-0.03
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
Book Value per Share
-0.02
0.08
0.05
0.04
Tangible Book Value per Share
-0.03
0.08
0.04
0.03
Basic Weighted Avg Shares
26
117
129
133
Sales/Revenue/Turnover
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
Net Income, GAAP
-2
-4
-4
-6
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
Working Capital
-1
9
5
5
LT Debt
- -
- -
- -
- -
Total Equity
-1
11
6
5
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-48.64
-109.48

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-14.13%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
48.44%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.03
2025
- -
- -
-0.03
2026
- -
- -
-0.04

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Richard Allman
Sector
Health technology
Industry
Medical specialties
Address
480 Collins Street Melbourne VIC Australia 3000
IPO Date
Aug 18, 2023
Website
cleodx.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
CLEO Diagnostics Ltd. is a medical diagnostics/devices company which mainly focuses on the development of non-invasive blood based IVD tests to detect the presence, and recurrence, of ovarian cancer. It developed a three-phased product development strategy that will deliver three related tests for ovarian cancer detection: Triage Test-a pre-surgical test, Recurrence Test-a post-surgical test and Screening Test-a screening test to identify early-stage ovarian cancer. The company was founded on November 30, 2021 and is headquartered in Melbourne, Australia.